Homogenous Good Outcome in a Heterogeneous Group of Tumors: An Institutional Series of Outcomes of Superficial Soft Tissue Sarcomas

Table 1

S-STS patient demographics, disease characteristics, and management.

	= 103
Age, years
Median (range)	55 (15–89)
Sex
Male	48 (46.6%)
Tumor location
Trunk	40 (38.8%)
Lower extremity	39 (37.9%)
Upper extremity	14 (13.6%)
Head and neck	8 (7.8%)
Vulva	2 (1.9%)
Tumor size
5 cm	79 (76.6%)
5 cm	21 (20.4%)
Unknown	3 (3.0%)
Histology
Leiomyosarcoma	37 (35.9%)
MFH^1	16 (15.5%)
Liposarcoma	8 (7.8%)
Pleomorphic sarcoma	8 (7.8%)
Myxofibrosarcoma	7 (6.8%)
Angiosarcoma	6 (5.8%)
Other^2	21 (20.4%)
Grade
Low	32 (31.0%)
Intermediate	7 (6.8%)
High	56 (54.4%)
Unknown	8 (7.8%)
Stage
I	31 (30.0%)
II	49 (47.6%)
III	22 (21.4%)
Unknown	1 (1.0%)
Surgery, resection
R0	95 (92.2%)
Wide (2 cm)	76 (80%)
Close (2 cm)	19 (20%)
R1	6 (5.8%)
Unknown	2 (1.9%)
Surgery, closure of defect
Skin graft	22 (21.4%)
Flap	14 (13.6%)
Radiation therapy
Preoperative	6 (5.8%)
Postoperative	16 (15.5%)
None	77 (74.8%)
Other^3	4 (3.9%)
Chemotherapy
Preoperative	5 (4.9%)
Postoperative	3 (2.9%)
None	95 (92.2%)

Malignant fibrous histiocytoma.
Including epithelioid sarcoma, fibrosarcoma, synovial sarcoma, clear cell sarcoma, primitive neuroectodermal tumor (PNET), malignant peripheral nerve sheath tumor (MPNST), and not otherwise specified (NOS).
Received after LR prior to excision.